- Home
- / Antibe Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Antibe Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.7
2021-01-28
Market Capitalization
$156.1 M
2021-01-28
Revenue
$7 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 8.5M | 9.5M | 10.0M | 9.9M | 13.5M | 7.0M |
| Cost of goods sold | 5.1M | 6.0M | 6.1M | 6.3M | 8.1M | 3.9M |
| Gross profit | 3.4M | 3.6M | 3.9M | 4.6M | 5.5M | 3.0M |
| Gross profit margin, % | 39.7% | 37.2% | 38.9% | 46.8% | 40.4% | 43.5% |
| Operating expense total | 9.7M | 15.3M | 18.3M | 28.6M | 27.4M | 18.0M |
| Depreciation and amortization | 377.0K | 416.0K | 1.9M | 478.0K | 99.0K | |
| EBITDA | (6.3M) | (11.8M) | (14.4M) | (24.0M) | (21.9M) | (15.0M) |
| EBITDA margin, % | -73.9% | -123.4% | -144.0% | -241.4% | -162.3% | -214.2% |
| EBIT | (6.7M) | (12.2M) | (16.2M) | (25.8M) | (22.0M) | (15.3M) |
| EBIT margin, % | -78.3% | -127.8% | -162.6% | -259.8% | -163.0% | -219.1% |
| Interest income | 17.0K | 31.0K | 99.0K | 46.0K | 282.0K | 1.4M |
| Interest expense | 1.2M | 430.0K | 500.0K | 230.0K | 8.0K | 8.0K |
| Pre tax profit | (7.7M) | (12.7M) | (19.3M) | (26.3M) | (25.1M) | (19.2M) |
| Income tax expense | (274.0K) | 135.0K | (7.0K) | 260.0K | ||
| Net Income | (7.4M) | (12.8M) | (19.3M) | (26.3M) | (25.1M) | (19.5M) |